Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Climb Bio Inc(CLYM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CLYM
09/15/2026: CLYM (1-star) is currently NOT-A-BUY. Pass it for now.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. Its primary strength lies in a specialized, asset-light research pipeline led by an experienced team. The central investment story centers on the potential of its clinical candidates to offer superior treatment options for chronic conditions. However, the company faces significant risks, including the inherent uncertainty of drug development, potential for clinical trial failure, and fierce competition from well-established pharmaceutical giants. The stock is best suited for risk-tolerant investors seeking exposure to innovation in biotechnology, and key developments to monitor include upcoming clinical trial data readouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The potential for high growth exists, but it is contingent upon high-risk, long-term clinical trial success. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of clinical data releases or positive trial announcements. |
| Value investor | Weak fit | The company lacks current earnings or traditional valuation metrics, making standard value analysis inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvesting capital. |
| Low-risk investor | Weak fit | High volatility and the inherent uncertainty of drug development make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are highly reactive to data readouts and regulatory updates. |
| Valuation risk | Medium / high | Without commercial revenue, valuation is speculative and highly dependent on future projections. |
| Competition risk (immunology/biopharma) | High | Well-capitalized incumbents hold dominant market positions and massive R&D budgets. |
| Business quality | Medium | Business quality is currently measured by R&D efficacy rather than market performance or margins. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | High | Clinical trial delays or failures could jeopardize the company's long-term viability. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -50.06% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 836.27M USD | Price to earnings Ratio - | 1Y Target Price 27.57 |
Price to earnings Ratio - | 1Y Target Price 27.57 | ||
Volume (30-day avg) 1.5M shares | Beta 0.1 | 52 Weeks Range 1.54 - 18.33 | Updated Date 09/15/2026 |
52 Weeks Range 1.54 - 18.33 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development Pipeline | Clinical and preclinical autoimmune therapeutic candidates. | The company is currently spending money to develop drugs, with no sales yet. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 635.22M | Price to Sales(TTM) - |
Enterprise Value 635.22M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 57.44M | Shares Floating 41.60M |
Shares Outstanding 57.44M | Shares Floating 41.60M | ||
Percent Insiders 0.37 | Percent Institutions 105.33 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Climb Bio Inc
Exchange NASDAQ | Headquarters Wellesley Hills, MA, United States | ||
IPO Launch date 2021-08-10 | CEO, President & Director Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://climbbio.com |
Full time employees 28 | Website https://climbbio.com | ||
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.